Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults by Andrew J Clifford et al.
Clifford et al. Lipids in Health and Disease 2013, 12:66
http://www.lipidworld.com/content/12/1/66RESEARCH Open AccessSingle nucleotide polymorphisms in CETP, SLC46A1,
SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are
significant predictors of plasma HDL in
healthy adults
Andrew J Clifford1*, Gonzalo Rincon2, Janel E Owens3, Juan F Medrano2, Alanna J Moshfegh4, David J Baer5
and Janet A Novotny5Abstract
Background: In a marker-trait association study we estimated the statistical significance of 65 single nucleotide
polymorphisms (SNP) in 23 candidate genes on HDL levels of two independent Caucasian populations. Each
population consisted of men and women and their HDL levels were adjusted for gender and body weight. We
used a linear regression model. Selected genes corresponded to folate metabolism, vitamins B-12, A, and E, and
cholesterol pathways or lipid metabolism.
Methods: Extracted DNA from both the Sacramento and Beltsville populations was analyzed using an allele
discrimination assay with a MALDI-TOF mass spectrometry platform. The adjusted phenotype, y, was HDL levels
adjusted for gender and body weight only statistical analyses were performed using the genotype association and
regression modules from the SNP Variation Suite v7.
Results: Statistically significant SNP (where P values were adjusted for false discovery rate) included: CETP
(rs7499892 and rs5882); SLC46A1 (rs37514694; rs739439); SLC19A1 (rs3788199); CD36 (rs3211956); BCMO1 (rs6564851),
APOA5 (rs662799), and ABCA1 (rs4149267). Many prior association trends of the SNP with HDL were replicated in our
cross-validation study. Significantly, the association of SNP in folate transporters (SLC46A1 rs37514694 and rs739439;
SLC19A1 rs3788199) with HDL was identified in our study.
Conclusions: Given recent literature on the role of niacin in the biogenesis of HDL, focus on status and
metabolism of B-vitamins and metabolites of eccentric cleavage of β-carotene with lipid metabolism is exciting for
future study.
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Understanding the effects of genetic, environmental, and
especially of lipid levels on health status, is of wide and sig-
nificant interest [1]. The relationships between persistent
environmental pollutants and micronutrient levels are not
well understood; though such speculation includes the role
of peroxisome proliferator-activated receptor (PPAR), tran-
scription factors related to lipid homeostasis, or changes in* Correspondence: ajclifford@ucdavis.edu
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reproduction in any medium, provided the orDNA methylation patterns [1]. In our recent work [2], we
investigated 65 single nucleotide polymorphisms (SNP) in
23 candidate genes involved in folate metabolism (8 genes),
vitamins B-12, A, and E metabolism (5 genes), and choles-
terol pathways or lipid metabolism (10 genes) in a homo-
cysteine/red blood cell folate marker trait association
study. Interestingly, a few SNP associated with diabetes
mellitus (DM), cardiovascular disease (CVD) and main-
tenance of the cholesterol pathway or lipid metabolism
were identified: serine palmitoyltransferase (SPTLC1 rs117
90991), cholesteryl ester transfer protein (CETP rs5882)
and scavenger receptor class B type 1 (SCARB1 rs838892).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Sacramento population
Gene SNP predictor P-value R2 ASE FDR MAF
CETP rs7499892 0.000437 0.098 −2.309 0.0015 0.15
CETP rs5882 2.16E-05 0.205 −10.250 0.0004 0.05
SLC46A1 rs35714695 2.62E-06 0.160 −6.644 0.0002 0.15
SLC46A1 rs739439 6.03E-06 0.207 −6.713 0.0002 0.17
SLC19A1 rs3788199 0.000209 0.226 2.828 0.0012 0.45
CD36 rs3211956 9.39E-08 0.183 4.372 1.14E-06 0.07
BCMO1 rs6564851 0.000456 0.114 0.586 0.0014 0.49
APOA5 rs662799 0.000491 0.148 −4.523 0.0013 0.05
ABCA1 rs4149267 4.59E-08 0.195 −3.236 9.76E-07 0.37
Significant SNP predictors on HDL concentrations (mg/dL) in the Sacramento
population (n = 249).
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cluding rs2118981 in the cellular retinol binding protein II
gene (CRBP2), which is important for vitamin A and retin-
oid transfer, and rs838892 SCARB1 (for tocopherols and
tocotrienols), were also statistically significant predictors in
the final model. Significantly, SNP in betaine-homocysteine
methyltransferase (BHMT rs3733890) and methylene tetra-
hydrofolate reductase (MTHFR rs1801131), both of which
are involved in one-carbon metabolism, were also included
in the final model that was previously described [2].
Given the establishment of these associations in our
previous work [2], further investigation of the relation of
folate, homocysteine (Hcy), and changes in plasma lipid
profiles was of significant research interest. High levels
of Hcy and changes in plasma lipids are independent
risk factors for development of CVD, and there may be a
connection between Hcy metabolism and lipid metabol-
ism [3]. Low levels of dietary folate, an important cofac-
tor in the metabolism of Hcy, led to increased levels of
serum and liver cholesterol in wild-type mice [4]. As
well, cholesterol metabolism may contribute to beneficial
effects of dietary folate supplementation [4]. Possible
connections, not yet fully supported by experimental
data, between folate levels and cholesterol biosynthesis
include endoplasmic reticulum stress, which activates
cholesterol biosynthesis genes, or through metabolic
processes involving choline. Choline provides methyl
groups for Hcy metabolism and is a precursor for cho-
line phospholipids, which are required for lipoprotein
secretion [4]. Additionally, serum lipid levels are risk fac-
tors for a number of adverse health outcomes, including
coronary heart disease (CHD), atherosclerosis, type 2
DM, stroke, and metabolic syndrome [1]. Lipid levels of
interest include triglycerides, low-density lipoprotein
(LDL), and high-density lipoprotein (HDL), especially as
recent work has indicated that HDL may not always be
protective against atherosclerosis [5,6]. Particularly, the
functionality and quality of HDL [7] in response to vas-
cular inflammation and oxidative stress [5] is an interes-
ting area of further study. HDL is required in the reverse
cholesterol transport (RCT) mechanism where excess
cholesterol is transferred from peripheral cells to the
liver for intestinal excretion [8]. Additionally, HDL has
anti-inflammatory and antioxidant effects and improves
endothelial function [8].
In this study we selected 65 SNP in 23 candidate genes
to perform a marker trait association study with plasma
HDL adjusted for gender and body weight in Caucasian
male and female study participants from two indepen-
dent populations (Sacramento, California, and Beltsville,
Maryland). Selected SNP corresponded to 8 genes asso-
ciated with folate metabolism, 5 genes associated with
vitamin B-12, vitamin A and vitamin E metabolism, and
10 genes associated with cholesterol pathways or lipidmetabolism. The overall objective of this study was to
determine if any of these SNP in the 23 candidate genes
had a statistically significant association with HDL.
Results
Significant SNP predictors
Tables 1 and 2 include significant SNP predictors on
HDL concentrations (mg/dL) that were validated in both
the Sacramento and Beltsville populations, respectively.
Each table lists the gene with corresponding statistically
significant SNP predictor (with associated P-value) and
the square of the correlation coefficient (R2) indicating
the proportion of response variation explained by the re-
gressors in the model. The ASE in Tables 1 and 2 repre-
sents the allele substitution effect, which is the slope
derived from the regression, and where a positive ASE
indicated a positive association with the adjusted HDL
and conversely, a negative ASE indicated a negative as-
sociation. The false discovery rate (FDR) was corrected
for any chance findings. The minor allele frequency
(MAF) is the frequency at which the less common allele
occurs in the population indicating also the frequency of
the allele causing the effect.
Statistically significant SNP predictors in the Sacramento
and Beltsville populations were similar between both
groups though there were some differences in the direc-
tionality and magnitude of the association between SNP
predictor and HDL. SNP of genes that were statistically
significant included: 1) cholesteryl ester transfer protein
(CETP; rs7499892 and rs5882); 2) proton-coupled folate
transporter (SLC46A1; rs35714695 and rs739439); 3)
reduced folate carrier (SLC19A1; rs3788199); 4) throm-
bospondin receptor (CD36; rs3211956); 5) beta-carotene
monooxygenase 1 (BCMO1; rs6564851); 6) apolipopro-
teinA-V (APOA5; rs662799); and 7) ATP-binding cassette
transporter member 1 (ABCA1; rs4149267).
The two SNP included in this study for CETP
(rs7499892 and rs5882) with MAF of ~0.16 and MAF
of ~0.04 for the rare allele, respectively, were statistically
Table 2 Beltsville population
Gene SNP predictor P-Value R2 ASE FDR MAF
CETP rs7499892 3.10E-05 0.097 −2.088 0.0002 0.16
CETP rs5882 9.57E-05 0.086 −2.145 0.0002 0.04
SLC46A1 rs35714695 6.21E-05 0.091 1.606 0.0002 0.17
SLC46A1 rs739439 8.33E-05 0.091 1.323 0.0002 0.18
SLC19A1 rs3788199 0.001037 0.085 1.796 0.0100 0.41
CD36 rs3211956 7.93E-05 0.089 1.774 0.0002 0.07
BCMO1 rs6564851 7.90E-05 0.088 1.015 0.0002 0.49
APOA5 rs662799 6.72E-05 0.091 −0.471 0.0002 0.06
ABCA1 rs4149267 0.00143 0.071 −2.070 0.0078 0.38
Significant SNP predictors on HDL concentrations (mg/dL) in the Beltsville
population (n = 532).
Clifford et al. Lipids in Health and Disease 2013, 12:66 Page 3 of 10
http://www.lipidworld.com/content/12/1/66significantly negatively associated with HDL-C in both the
Sacramento and Beltsville populations (Tables 1 and 2) as
indicated by the ASE (slope of the regression). It was de-
termined that the rs3788199 SNP in SLC19A1 was posi-
tively correlated with HDL levels (ASE = 2.828 for the
Sacramento population, Table 1; ASE = 1.796 for the
Beltsville population, Table 2). The SNP rs35714695 and
rs739439 of SLC46A1 were both negatively associated with
HDL levels in the Sacramento population though the
Beltsville population had a positive association with HDL
levels, which indicates that the allele effects are opposite.
The directionality of this association difference is one area
of future study. In the present study, a very large positive
association between HDL levels and the presence of
rs3211956 of CD36 was also identified for both study po-
pulations (Table 1 and Table 2). In the Sacramento popu-
lation, the ASE was 4.372, with similar positive association
(but not as large) found in the Beltsville population
(ASE = 1.774). The results of the present study support a
past finding: in both populations (Sacramento and
Beltsville), a positive association, as indicated by the posi-
tive ASE values (Table 1, ASE = 0.586 and Table 2, ASE =
1.015), was established for the rs6564851 SNP of BCMO1
and plasma HDL levels. For APOA5, the rs662799 SNP
was statistically significantly negatively associated with
HDL. The ASE was −4.523 for the Sacramento population
(Table 1) and −0.471 for the Beltsville population (Table 2),
indicating that there was a negative association of the
presence of this SNP with measured HDL concentrations.
Finally, the SNP rs4149267 of ABCA1 was associated with
HDL-C in both Caucasian populations with similar
ASE of −3.236 in the Sacramento population (Table 1)
and −2.070 in the Beltsville population (Table 2).
Discussion
CETP
CETP encodes cholesteryl ester transfer protein, which
exchanges the triglycerides from VLDL and LDL parti-
cles for cholesterol esters from HDL. CETP alsoselectively enhances liver HDL cholesterol ester uptake
[9]. Inhibiting CETP with various pharmacologic agents
(torcetrapib, dalcetrapib, anacetrapib, evacetrapib) has
been an attractive means to minimize risk for adverse
cardiovascular events because of a potential rise in
HDL-C and fall in LDL-C [8,10]. Understanding the mo-
lecular basis for cholesteryl ester transport by CETP is
of research interest to support the development of other
CETP inhibitors [11]. In a previous genome wide associ-
ation study (GWAS), the SNP rs708272 (or TaqIB SNP)
of CETP had the strongest association with HDL-C of all
948 SNPs genotyped in 122 genes though this SNP was
not included in our study. As well, this SNP had a strong
association with apolipoproteinA-1 (apoA1) [12]. In a
population of Chinese Bama Zhuang individuals, the
rs708272 SNP was associated with higher HDL-C levels,
but the outcome of this SNP on longevity was less clear
[13]. A recent meta-analysis of 46 lipid GWAS, six
HDL-C loci were identified with at least a second inde-
pendent association with HDL-C including LPL, ABCA1,
APOA1/A4/A5/C3, ZNF664, LIPC, and CETP [14]. Both
ABCA1 and CETP were validated in our study. Tietjen
and colleagues showed that rare coding and splicing mu-
tations on CETP were enriched in persons with hyperal-
phalipoproteinemia and segregated with elevated HDL-C
in families [15].
In our prior study, rs5882 of CETP was statistically
significantly associated with Hcy normalized by red
blood cell folate concentrations [2]. Two of the four
SNP included in this study for CETP (rs7499892 and
rs5882) were statistically significantly negatively associ-
ated with HDL-C in both the Sacramento and Beltsville
populations (Tables 1 and 2). The rs5882 SNP has been
associated with lower CETP serum concentrations and ac-
tivity, increased HDL cholesterol levels, and increased
lipoprotein sizes, all factors which have been associated
with a lower CVD risk [16]. In a recent study in Tunisian
population, there was no statistically significant asso-
ciation of the rs5882 SNP with lipoprotein metabolism or
atherogenicity [17].
SLC46A1 and SLC19A1
The proton-coupled folate transporter (PCFT, gene
symbol SLC46A1) mediates intestinal folate absorption
and folate transport across the choroid plexus. PCFT has
an optimal pH transport of 5.0 – 5.5 (jejunum and duode-
num), but the role of this transporter in other tissues at
normal physiological pH is less clear [18]. Homozygous
mutations in SLC46A1 have been associated with a rare
disorder, hereditary folate malabsorption [18]. Solute car-
rier family 19 (folate transporter) member 1, also known
as the reduced folate carrier (RFC; gene symbol SLC19A1),
is involved in the regulation of intracellular concentrations
of folate. Higher serum folate concentrations have been
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HDL-C ratio, and higher HDL-C. These associations were
independent of gender or age, though influences of medi-
cations, diseases, physical exercise, diet, or BMI were not
accounted for in that study. Interestingly, vitamin B12 was
not associated with the lipoprotein profile in that reported
study [19]. Cholesterol may be important for facilitating
the import of folate by clustering membrane-bound folate
receptors in the cell membrane [19]. Use of clustering
membrane-bound folate receptors was favoured when fo-
late status was low [20]. Folate status is inversely associ-
ated with obesity [21], likely due to increased activity of
COMT (catechol O-methyltransferase), which uses folate
for methyl transfer for metabolism of catechol estrogen
produced by adipose tissue. Both obesity [21] and low fol-
ate status [19] have been associated with reduced HDL
cholesterol levels. However, in a recent study examining
folate placental transport in obese women, it was deter-
mined that while protein expression of folate receptor-α
and RFC were altered (PCFT was unchanged), the activ-
ities of the transporters was unaltered in obesity and fetal
folate serum concentration were not adversely affected
[22]. In the present study, it was determined that the
rs3788199 SNP in SLC19A1 was positively correlated with
HDL levels (ASE = 2.828 for the Sacramento population,
Table 1; ASE = 1.796 for the Beltsville population, Table 2),
which compares well to the earlier retrospective database
study previously described [19]. Surprisingly, it was also
determined that the SNP rs35714695 and rs739439 of
SLC46A1 were both negatively associated with HDL levels
in the Sacramento population whereas the Beltsville popu-
lation had a positive association with HDL levels, which
indicates that the allele effects are opposite. To our know-
ledge, there are no studies providing information on asso-
ciation studies of SNP in SLC46A1 with HDL cholesterol
levels. Given the differences in association between the
two populations in this study, investigation of SNP in
SLC46A1 with HDL is of further research interest.
A 2010 study examined seven SNP variants in genes
involved in Hcy metabolism on the interaction with
plasma lipid profile. In that study, SLC19A1 (SNP
rs1051266) was not found to have a statistically signi-
ficant association with blood lipid profiles analysed
(fasting lipoprotein, total cholesterol, LDL, HDL, and
triglyceride levels) [3]. Additional findings from that
study implicated SNP in the genes for transcobalamin
II (rs1801198) and MTHFR (rs1801133) were associated
with blood lipid profiles. The G allele of rs1801198 was
correlated with higher levels of LDL in plasma, lower
HDL, higher triglyceride levels, and higher total cho-
lesterol levels [3]. However, in our study, neither
rs1801198 (transcobalamin II) nor rs1801133 (MTHFR)
were statistically significantly associated with levels of
HDL in plasma.CD36
CD36 (thrombospondin receptor), or glycoprotein IIIb/
platelet glycoprotein IV is a mediator of platelet adhe-
sion to collagen. The investigation of SNP of CD36 on
HDL is not well established, likely because participants
in many studies deal with chronic diseases, including
DM, CHD, or metabolic syndrome or risk factors for
chronic diseases [23-26]. Therefore, CD36 warrants fur-
ther investigation, with careful statistical control of po-
tentially confounding variables, including environmental
factors, dietary factors, and other genotypes. In our
study, we enrolled healthy participants as indicated by
low use of statins (less than ~7% for overall study popu-
lation) and healthy BMI (mean ± standard deviation for
Sacramento was 24.8 ± 4.2 and 26.6 ± 4.6 for Beltsville).
We found that there was a very large positive association
between HDL levels and the presence of SNP rs3211956
(Tables 1 and 2). In the Sacramento population the ASE
was 4.72, with similar positive association (but not as
large) found in the Beltsville population (ASE=1.774).
BCMO1
Beta-carotene monooxygenase 1 (BCMO1) catalyzes the
first step in the central cleavage and conversion of die-
tary provitamin carotenoids to vitamin A (retinal) in the
small intestine [27,28]. Vitamin A is necessary for im-
mune response, vision, embryonic development, cell dif-
ferentiation, and membrane and skin protection [27].
The statistically significant SNP identified in the present
study, rs6564851, is 7.7 kb 5’ upstream from the BCMO1
gene. This particular SNP has been associated with a
48% reduced catalytic activity of converting β-carotene
into vitamin A in female participants in a recent stu-
dy [29]. Other SNP in BCMO1 have been associated
with plasma levels of various carotenoids, including β-
carotene, lutein, α-carotene, zeaxanthin, and lycopene
[27]; and the G allele of the rs6564851 may explain some
of the variance in plasma levels of these provitamin
carotenoids. The rs6564851 SNP may be particularly
important for individuals at risk for vitamin A deficiency
[27] owing to reduced catalytic activity of BCMO1 [29].
Recently, the rs6564851 SNP had the strongest associ-
ation (when compared to other SNP: rs11645428,
rs6420424, and rs8044334) with fasting β-carotene con-
centrations in plasma [29]. Higher levels of carotenoids
(isomers of β-carotene, lycopene, and β-cryptoxanthin)
have been associated with higher levels of HDL and LDL
in a recent study involving NHANES participants [1]. In
a recent review, the important physiological effects of
eccentric cleavage products of beta-carotene were
discussed. Considering the effects of BCMO1 SNP as
well, there could be some very different physiological ef-
fects from beta-carotene consumption owing to genetic
influences, oxidative stress, and presence of various
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has focused on the retinoid receptor antagonist activity
of products resulting from β-carotene eccentric cleavage,
the β-apocarotenoids [30,31]. The biological activities
and effects of these β-carotene metabolites may be
important to consider in evaluating oxidative stress and
adverse health outcomes of CVD or cancer [30]. It has
been established that there is no association between the
BCMO1 SNP rs6564851 and risk of developing type 2
DM [32].
APOA5
ApolipoproteinA-V is a protein component of HDL. In
this study, the rs662799 SNP of APOA5 was identified as
being a significant predictor. The ASE was −4.523 for
the Sacramento population and −0.471 for the Beltsville
population, indicating that there was a negative associ-
ation of the presence of this SNP with measured HDL
concentrations. In a recent study [33], the rs662799 SNP
was the only SNP (of thirteen evaluated in the APOA1/
C3/A4/A5 gene cluster) to be associated with three lipid
traits: triglycerides, HDL-C, and LDL-C levels. In this
past study, the MAF was statistically significantly associ-
ated with familial combined hyperlipidaemia, though the
functional effect of this rs662799 SNP may not be well
understood [33]. In another recent study, rs662799 was
statistically significantly associated with plasma triglycer-
ides in both women and men of the study population
and statistically significantly associated with total cho-
lesterol and LDL-C levels in men only. However, the
authors concluded that haplotypes for five SNP in the
apolipoprotein A1/C3/A5 cluster could explain more
serum lipid variation than any one SNP alone, especially
for HDL-C [34]. The presence of the rs662799 SNP was
statistically significantly associated with lower levels of
total cholesterol, triglycerides, and LDL-C in a group of
Hei Yi Zhuang Chinese (though this same trend was not
observed in Han Chinese), indicating that there may be
other gene-gene or gene-environment interactions [35].
ABCA1
ABCA1 (ATP-binding cassette transporter member 1)
plays an important role in cellular cholesterol and
phospholipid homeostasis in multiple cell types [36,37]
and is involved in RCT [38]. ABCA1 mediated efflux of
cholesterol and phospholipids leads to the formation of
nascent HDL via apoA1 [39,40]; and mutations that
disrupt normal ABCA1 function result in little or no cir-
culating HDL [41]. ABC transporter G1 (ABCG1) pro-
motes cholesterol efflux from macrophages to HDL to
form mature HDL particles [40], and hence works in a
sequential manner with ABCA1 [42]. All trans-retinoic
acid has been shown to increase apoA1/HDL-mediated
cholesterol efflux from macrophages by increasing ABCA1and ABCG1 by regulating promoter activity via liver X
receptor-responsive element mechanism [42]. Wiersma
and colleagues [43] also showed that ABCG1 knock-out
mice exhibit decreased HDL-C when consuming a high
fat diet. In this study, they also demonstrated that ABCG1
mediated cholesterol efflux to HDL [43]. Functional mu-
tations in ABCA1 cause Tangier disease, which is charac-
terized by very low levels of plasma HDL apoA1 [44,45].
In a recent study investigating exome sequencing, func-
tional rare variants in ABCA1 and LPL (gene for lipopro-
tein lipase) were identified and explained a major portion
of the HDL-C variance in the population enrolled in the
study [41].
Previous studies have found associations between cer-
tain SNP in ABCA1 and HDL concentrations [46-48]. Re-
cent GWAS and meta-analysis studies showed that SNP
in ABCA1 were significantly associated with HDL-C
[14,49]. In our study, the SNP rs4149267 of ABCA1 was
associated with HDL-C in both Caucasian populations
with similar ASE of −3.236 in the Sacramento population
and −2.070 in the Beltsville population.
It would be significant to understand the effects of
apolipoprotein E (apoE), which plays an important role
in lipoprotein metabolism and atherosclerosis. ApoE has
been shown to promote selective uptake of HDL-C
owing to increased ABCA1-mediated cholesterol efflux
to plasma [50]. This present work identifies significant
SNP in ABCA1 and hence this relation with ABCA1
SNP and apoE facilitated HDL-C transport is of future
research interest.
Conclusions
The strength of our study is the cross-validation be-
tween two independent populations (one on the West
coast, from Sacramento, CA, and one from the East
coast, from the Washington, D.C. area) with similar SNP
associations identified in both populations. It would
be of significant research interest to focus on the rela-
tion of B vitamins on HDL status. In this work, we have
identified SNP in two folate transporters (SLC46A1
rs35714695 and rs739439; SLC19A1 rs3788199) having
statistically significant ASE in relation to HDL status in
both study populations. Cholesterol may be important
for facilitating the import of folate across the cell mem-
brane and higher serum folate concentrations have been
associated with lower levels of LDL-C and higher levels
of HDL-C [19]. Past work by Kitami et al. focused on
the importance of the homeostatic role of cholesterol
metabolism on folate retention in mouse strains, so
there has been an established relationship between cho-
lesterol and folate in the mouse [4]. Recent work by
Zhang et al. identified the role of niacin (also known as
vitamin B3) on early hepatic HDL formation through
transcription of ABCA1. In that study, apoA1 lipidation
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bilized by niacin, which may prevent premature HDL
catabolism [51].
Finally, the identification of the positive association of
the BCMO1 SNP rs6564851 with HDL levels was of sig-
nificance. This SNP has a high MAF in the two inde-
pendent study populations of this work (Tables 1 and 2).
Additionally, the presence of this SNP has been asso-
ciated with a 48% reduction in activity of converting
β-carotene into vitamin A through central cleavage,
resulting in higher circulating levels of plasma carote-
noids [29]. These higher levels of carotenoids may be
associated with higher levels of HDL and LDL [1]. The
biological effects of the eccentric cleavage products of
β-carotene (the apo-β-carotenoids), especially on lipid





The Institutional Review Board of the University of
California, Davis, approved the study, which was con-
ducted according to Good Clinical Practice guidelines and
the Declaration of Helsinki, version 1989. Written in-
formed consent was obtained from each participant before
enrollment in the study. Women and men ranging in age
from 18 to 67 years were recruited by posted, published,
and mailed advertisements in the California counties of
Sacramento, San Joaquin, Solano, and Yolo from May
2004 through August 2005. Persons were excluded for any
history of a serious medical condition, for using medica-
tions that could interfere with folate metabolism (inclu-
ding phenytoin, primidone, fosphenytoin, carbamazepine,
phenobarbital, ranitidine, trimethoprim, metformin, sulfa-
salazine, triamterene or methotrexate, beta blockers, and
angiotensin inhibitors), for using tobacco, or for heavy
consumption of alcohol (≥ 3 drinks per day). Responders
to advertisements enrolled in a single clinic visit at the
Ragle Human Nutrition Research Center at the University
of California, Davis. Before the clinic visit, participants in
the study received via US mail a packet containing infor-
mation about the study, consent forms, instructions to fast
for 8 – 10 h prior to the clinic visit, and two dietary intake
instruments to assess folate intake from the diet and sup-
plements. Folate intake assessed by the Block Dietary
Folate Equivalents (DFE) Screener is available through
Supporting Information (Additional file 1: Figure S1). At
the time of the scheduled visit, participants were inter-
viewed about general medical, personal, and family histo-
ries. Gender, age, and BMI (calculated from height and
weight measurements) were also recorded. Fasting whole
blood samples were then drawn as described below. A $15
gift certificate to a local supermarket or department storewas given to each person at the end of the clinic visit.
Two hundred forty-nine individuals were enrolled in the
Sacramento population.
Beltsville population
The Johns Hopkins University Bloomberg School of
Public Health Committee on Human Research approved
the study procedures and protocol, which was in accord
with Good Clinical Practice guidelines and the De-
claration of Helsinki, version 1989. The population con-
sisted of 510 adults (257 females, 253 males) aged
30 – 69 years residing in the greater Washington, D.C.
area. Participants were recruited to participate in a study
of dietary recall between July 2002 and June 2004 [52]
and were included in the present study as an adjunct to
the previous study. Potential participants were recruited
through email, advertisements in local newspapers, and
announcements on USDA ARS websites. Participants
attended an informational meeting concerning study
procedures before completing a health history question-
naire. The questionnaire covered general medical, per-
sonal, and family histories. Folate intake assessed by the
Block Dietary Folate Equivalents (DFE) Screener is avai-
lable through Supporting Information (Additional file 1:
Figure S1). A medical screening evaluation included
measurement of height, weight, blood pressure, and la-
boratory analysis of fasting blood and urine. Age, BMI
(calculated from height and weight measurements) and
gender were also recorded. The medical history and la-
boratory results were reviewed by study investigators
and a cooperating physician to confirm good health of
the participants and that there was no evidence of
underlying disease, untreated thyroid disorders, gastro-
intestinal disease, malabsorption syndromes, history of
eating disorders, cancer, or DM. All participants were
weight stable, were not actively pursuing a weight-loss
regimen, were not taking medications known to affect
food intake or appetite, and were not taking diuretics or
other medications that may affect water balance. Preg-
nant and lactating women were excluded from the study.
Participants were compensated according to the require-
ments of the main study [52].
Blood analysis and genotyping
Sacramento population
Fasting whole blood was collected in triplicate. It was
collected 1) into spray-dried K2EDTA tubes for assess-
ment of complete blood count, red blood cell (RBC) fol-
ate, plasma vitamin B6, and plasma Hcy; 2) into serum
separator tubes for the assessment of serum vitamin
B12, serum folate, and lipid panel; and 3) into 8.5-mL
whole blood DNA tubes for the assessment of genomic
DNA. The preparation and analysis of the collected
Table 3 SNP included in analyses
Name Gene, function Chromosome dbSNP identifier n
Apolipoprotein A1 APOA1, protein component of HDL, promotes
cholesterol efflux from tissues to liver
11 rs2727784 1





ATP-binding cassette, subfamily A,
member 1
ABCA1, transport AAs, sugars, vitamins, cholesterol,




β-Carotene 15,15’-monooxygenase 1 BCMO1, cleave β-carotene 16 rs12934922, rs6564851,
rs7501331
3





BHMT, methylate Hcy 5 rs3733890 1
Cholesteryl ester transfer protein,
plasma
CETP, transfer cholesterol 16 rs12708980, rs5880, rs5882,
rs7205804, rs7499892
5
Cystathionine β-synthase CBS, synthesize cystathionine 21 rs5742905 1
Cytochrome P450, family 4, subfamily
F, polypeptide 2




(prostate specific membrane antigen) 1
FOLH1 (GCPII), hydrolyze folate 11 rs61886492 1
Methionine synthase reductase MTRR, remethylate Hcy 5 rs1801394 1
Methylenetetrahydro-folate reductase MTHFR, distribute one carbon units 1 rs1801131, rs1801133 2
5-Methyltetra-hydrofolate-
homocysteine methyltransferase
MTR, remethylate Hcy 1 rs1805087 1
Microsomal triglyceride transfer
protein
MTTP, lipoprotein assembly 4 rs10516445, rs1057613,
rs3828542, rs881980
4
Niemann-Pick disease, type C1,
gene-like 1





Retinol binding protein 1, cellular CRBP2 (RBP2), 3 rs2118981, rs35674260,
rs3772875
3
Scavenger receptor class B, member 1 SCARB1, intestinal absorption of carotenoids 12 rs10773105, rs12582221,
rs7306660, rs7967521, rs838892
5
Serine palmitoyltransferase, long chain
base subunit 1
SPTLC1, sphingolipid biosynthesis 9 rs11790991, rs2297568,
rs7858659
3
Solute carrier family 19
(folate transporter), member 1
SLC19A1, reduced folate carrier 21 rs13050920, rs3788205,
rs3788199
3
Solute carrier family 46
(folate transporter), member 1









α-Tocopherol transfer protein α-TTP, transport α-tocopherol 8 rs4501570, rs4587328, rs4606052 3
Transcobalamin II TCII, transport vitamin B12 22 rs1801198 1
Total SNP included in analysis 65
Information regarding the 65 SNP included in the analysis. In the last column, n denotes the number of SNP per gene.
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sults of RBC folate concentrations and plasma vitamin
B12 levels are included in the online Supporting Infor-
mation (Additional file 1: Figures S2 and S3). Briefly and
specifically to this study, the lipid panel was completed
using the Beckman LXI and LX20 Pro (Beckman Instru-
ments, Brea, CA) at the Department of Pathology labo-ratory of the University of California, Davis. Results of
serum triglycerides, total cholesterol, HDL-C, and LDL-
C are provided in the online Supporting Information
(Additional file 1: Figures S4 S5, S6, S7). Additionally,
genomic DNA was extracted from whole blood with the
use of a PAXgene Blood DNA kit (PreAnalytix; Qiagen,
Inc., Valencia, CA).
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Blood was collected into serum separator tubes after a
12 h fast. Blood samples were allowed to sit for 30 min
before centrifugation at 2000 × g for 10 min at 4°C then
aliquotted and stored at −80°C until analysis. Plasma-
deplete samples were analysed for folate concentration
as described previously [2]. The results of RBC folate
concentrations and plasma vitamin B12 levels are in-
cluded in the online Supporting Information (Additional
file 1: Figures S2 and S3). Thawed samples were analyzed
in duplicate for HDL cholesterol on a Dade Behring
Dimension xPand clinical chemistry analyzer (Siemens,
Erlangen, Germany). Results of serum triglycerides, total
cholesterol, HDL-C, and LDL-C are provided in the online
Supporting Information (Additional file 1: Figures S4, S5,
S6, S7). High quality DNA was extracted from white blood
cells using the Gentra PureGene Blood DNA Purification
Kit (Qiagen, Inc.) as was previously described [2] prior to
SNP analysis.
Genotyping of SNP
Extracted DNA from both the Sacramento and Beltsville
populations was analyzed using an allele discrimination
assay with a MALDI-TOF mass spectrometry plat-
form (Sequenom MassARRAYW) (Neogen/GeneSeek Inc.,
Lincoln, NE). A total of 65 SNP in 23 genes were
analysed. Candidate gene selection was performed based
upon a literature search of pathways involving folate,
lipids, vitamins A, E, and B12 metabolism. Specific SNP
in relevant genes were obtained from dbSNP [53] and
Ensembl [54] databases (Table 3).
Data processing and statistical analysis
Association analysis
Marker-trait association analysis was performed using a
linear regression test under an additive model assump-
tion in Caucasian participants from both study popula-
tions only. The adjusted phenotype, y, was HDL levels
adjusted for gender and body weight only (see discussion
in Statistical significance of fixed effects, below). Statis-
tical analyses were performed using the genotype associ-
ation and regression modules from the SNP Variation
Suite (SVS) version 7 (Golden Helix Inc., Bozeman,
MT). In brief, the adjusted phenotype, y, was fit to every
encoded genotype under an additive model assumption,
x, and was represented with the following equation (1):
y ¼ b1xþ b0 þ ε ð1Þ
Where y was the adjusted phenotype (HDL adjusted
for gender and weight), b1x + b0 represented the model,
and the error term, ε, expressed the random residual
effect.Statistical significance of fixed effects
Participant data (gender, age, height, weight, and calcu-
lated BMI) were tested to adjust phenotypes for systematic
effects using a full (including covariates) versus reduced
model regression equation. The regression sums of
squares were calculated both for a reduced and for the full
model. An F test was then performed to find the signifi-
cance of the full versus the reduced model. A P-value
threshold of 0.01 was used to establish significant associa-
tions. Gender and body weight effects were statistically
significant; therefore, adjusted phenotypes were obtained
for all samples.
The linear regression was also performed including SNP
interactions using the SVS version 7 regression module
from Golden Helix. FDR was controlled according to a
previous method [55] and a cutoff for a significant associ-
ation value was set at FDR q value < 0.01.Additional file
Additional file 1: Figure S1. Diet Folate Equivalent (DFE) histogram of
Sacramento (n = 248) and Beltsville (n = 505) study participants. Figure
S2: Red Blood Cell (RBC) folate concentrations histogram of Sacramento
(n = 248) and Beltsville (n = 509) study participants. Figure S3:
Comparison of plasma vitamin B12 concentrations (pg/mL) in the
Sacramento and Beltsville populations. Figure S4: Comparison of serum
triglyceride levels in the Sacramento (n = 248) and Beltsville (n = 505)
study participants. Figure S5: Comparison of total cholesterol (mg/dL) in
the two study populations. Figure S6: Comparison of HDL cholesterol
(mg/dL) in the two study populations. Figure S7: Comparison of LDL
cholesterol (mg/dL) in the two study populations.Abbreviations
SNP: Single nucleotide polymorphism(s); HDL and HDL-C: High-density
lipoprotein high-density lipoprotein cholesterol; CETP: Gene symbol for
cholesteryl ester transfer protein; SLC46A1: Gene symbol for solute carrier
family 46 (folate transporter), member 1 or proton-coupled folate transporter;
SLC19A1: Gene symbol for solute carrier family 19 (folate transporter),
member 1, or reduced folate carrier; CD36: Gene symbol for
thrombosponding receptor or glycoprotein IIIb/platelet glycoprotein IV;
BCMO1: Gene symbol for beta-carotene monooxygenase 1; APOA5: Gene
symbol for apolipoproteinA-V; ABCA1: Gene symbol for ATP-binding cassette
transporter member 1; PPAR: Peroxisome proliferator-activated receptor;
DM: Diabetes mellitus; CVD: Cardiovascular disease; SPTLC1: Gene symbol for
serine palmitoyltransferase; SCARB1: Gene symbol for scavenger receptor
class B type 1; CRBP2: Gene symbol for cellular retinol binding protein;
BHMT: Gene symbol for betaine-homocysteine methyltransferase;
MTHFR: Gene symbol for methylene tetrahydrofolate reductase;
Hcy: Homocysteine; CHD: Coronary heart disease; LDL and LDL-C: Low-
density lipoprotein and low-density lipoprotein cholesterol; RCT: Reverse
cholesterol transport; ASE: Allele substitution effect; FDR: False discovery rate;
MAF: Minor allele frequency; VLDL: Very low-density lipoproteins;
CETP: Cholesteryl ester transfer protein; GWAS: Genome-wide association
study; apolA1: Apolipoproteina-1; PCFT: Proton-coupled folate transporter;
RFC: Reduced folate carrier; COMT: Catechol O-methyltransferase;
CD36: Thrombosponding receptor or glycoprotein IIIb/platelet glycoprotein
IV; BMI: Body mass index; BCMO1: Beta-carotene monooxygenase 1;
NHANES: National Health and Nutrition Examination Survey;
APOA5: Apolipoproteina-V; ABCA1: ATP-binding cassette transporter member 1;
ABCG1: ATP-binding cassette transporter G1; LPL: Gene symbol for lipoprotein
lipase; apoE: Apolipoprotein E; K2EDTA: Potassium ethylenediaminetetraacetic
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